Dogwood Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
DWTX$1.20-6.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Exhibit Index
| ExhibitNo. | Description | |
| | ||
| 3.1 | | Certificate of Designation of Series A-2 Non-Voting Convertible Preferred Stock of Dogwood Therapeutics, Inc. dated September 29, 2025 (incorporated by reference herein from Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on September 29, 2025). |
| | | |
| 4.1 | | Specimen Certificate evidencing shares of the Registrant’s common stock (incorporated by reference herein from Exhibit 4.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on October 16, 2020). |
| | | |
| 10.1 | | Exclusive License Agreement, dated September 29, 2025, by and between Dogwood Therapeutics, Inc. and Serpin Pharma, Inc. (incorporated by reference herein from Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on September 29, 2025). |
| | | |
| 10.2 | | Equity Issuance and Registration Rights Agreement, dated September 29, 2025, by and among Dogwood Therapeutics, Inc., Serpin Pharma, Inc. and Rejuvenation Labs, Inc. (incorporated by reference herein from Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on September 29, 2025). |
| | | |
| 10.3 | | Support Agreement, dated September 29, 2025, by and among Dogwood Therapeutics, Inc., Serpin Pharma, Inc. and Rejuvenation Labs, Inc. (incorporated by reference herein from Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed with the SEC on September 29, 2025). |
| | | |
| 10.4 | | Form of Support Agreement by and among Dogwood Therapeutics, Inc. and certain affiliates of Tungsten Advisors (incorporated by reference herein from Exhibit 10.4 to the Company’s Current Report on Form 8-K, filed with the SEC on September 29, 2025). |
| | | |
| 10.5 | | Support Agreement, dated September 29, 2025, by and between Dogwood Therapeutics, Inc. and Sealbond Limited (incorporated by reference herein from Exhibit 10.5 to the Company’s Current Report on Form 8-K, filed with the SEC on September 29, 2025). |
| | | |
| 31.1† | | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| | ||
| 31.2† | | Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| | ||
| 32.1† | | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| | ||
| 32.2† | | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| | | |
| 101.INS† | | XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
| | ||
| 101.SCH† | | XBRL Taxonomy Extension Schema Document |
| |
| 101.CAL† | | XBRL Taxonomy Extension Calculation Linkbase Document |
|---|---|---|
| | ||
| 101.DEF† | | XBRL Taxonomy Extension Definition Linkbase Document |
| | ||
| 101.LAB† | | XBRL Taxonomy Extension Label Linkbase Document |
| | ||
| 101.PRE† | | XBRL Taxonomy Extension Presentation Linkbase Document |
| | | |
| 104† | | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
| † | Filed herewith. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.